There are currently no known outstanding effects for the The Misuse of Drugs Regulations 2001, Paragraph 5.
[F15. A liquid formulation—U.K.
(a)containing a botanical extract of cannabis—
(i)with a concentration of not more than 30 milligrams of cannabidiol per millilitre, and not more than 30 milligrams of delta-9-tetrahydrocannabinol per millilitre, and
(ii)where the ratio of cannabidiol to delta-9-tetrahydrocannabinol is between 0.7 and 1.3,
(b)which is dispensed through a metered dose pump as a mucosal mouth spray, and
(c)which was approved for marketing by the Medicines and Healthcare Products Regulatory Agency on 16th June 2010]
Textual Amendments
All content is available under the Open Government Licence v3.0 except where otherwise stated. This site additionally contains content derived from EUR-Lex, reused under the terms of the Commission Decision 2011/833/EU on the reuse of documents from the EU institutions. For more information see the EUR-Lex public statement on re-use.
